Table 1.
| ||||||||
---|---|---|---|---|---|---|---|---|
entrya | catalystb,c | d | 4a | 5a | entrye | 4b | 5b | |
1 | Rh2(esp)2 | 35% | 17% | 9 | 5% | 80% | ||
2 | AgOTf/phen | 79% | --- | 10 | 80% | 14% | ||
3 | AgOTf/bipy | 60% | --- | 11 | 68% | 11% | ||
4 | AgOTf/bathophen | 57% | --- | 12 | 84% | 12% | ||
5 | AgOTf/p-MeObipy | 72% | --- | 13 | 73% | 11% | ||
6 | AgOTf/dafone | 32% | --- | 14 | 59% | 22% | ||
7 | AgOTf/p-Ph-bipy | 66% | --- | 15 | 62% | 20% | ||
8 | AgOTf/terpy | 27% | 35% | 16 | 9% | 61% |
Substrate 3a.
5 mol % Rh2(esp)2, 2 equiv PhlO.
Ag: 20 mol % AgOTf, 25 mol % ligand, 2 equiv PhIO, 4 Å MS, CH2Cl2.
A: aziridination. I: insertion.
Substrate 3b.